Article
Oncology
Hai-Bo Sun, Sen Yan, Xian-Ben Liu, Wen-Qun Xing, Pei-Nan Chen, Shi-Lei Liu, Peng Li, Ya-Xing Ma, Toni Lerut, Ahmed Daoud, Duo Jiang, Hai-Bo Sun
Summary: The study demonstrates that neoadjuvant chemotherapy (NAC) plus surgery prolongs overall survival (OS) and disease-free survival (DFS) and significantly decreases the rate of recurrence in patients with clinical stage II and III esophageal squamous cell carcinoma (ESCC) compared with surgery plus adjuvant chemotherapy (AC).
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Moath Said Alfawara, Ahmed Ibrahim Ahmed, Jean Michel Saad, Yushui Han, Fares Alahdab, Mahmoud Al Rifai, Mahwash Kassi, Talal Alnabelsi, William A. Zoghbi, Mouaz H. Al-Mallah
Summary: This study evaluated the use of serum beta-hydroxybutyrate (BHB) to identify adequate suppression of the left ventricle (LV) in patients undergoing cardiac inflammatory/infectious studies. The results showed that serum BHB level can be used to determine sufficient LV suppression.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Jiahuang Liu, Xiangming Che, Jiangtao You, Guangjian Zhang, Rui Zhao, Junke Fu, Haijun Li
Summary: Nampt, including iNampt and eNampt, may play a role in modulating obesity-related malignancies and affecting the response to chemotherapy in various cancers. This study found that iNampt expression increased in ESCC patients, while eNampt significantly elevated in obese patients and correlated positively with various body weight indicators. iNampt and age were independent predictors of ESCC response to neo-adjuvant chemotherapy, and factors like iNampt, ypN stage, and TRG were associated with ESCC survival.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Jun Yin, Jingnan Yuan, Yunjin Li, Yong Fang, Ruoxi Wang, Heng Jiao, Han Tang, Shaoyuan Zhang, Siyun Lin, Feng Su, Jianmin Gu, Tian Jiang, Dong Lin, Zhiliang Huang, Chaoxiang Du, Kui Wu, Lijie Tan, Qing Zhou
Summary: This study reported a phase 1b trial of neoadjuvant PD-L1 blockade with adebrelimab in resectable esophageal squamous cell carcinoma (ESCC). The results showed that the use of adebrelimab was safe and feasible, with some patients achieving a complete pathologic response. Responsive patients had an improved immune microenvironment at baseline.
Article
Oncology
Sangwon Han, Sae Byul Lee, Gyungyub Gong, Jungbok Lee, Sun Young Chae, Jungsu S. S. Oh, Dae Hyuk Moon
Summary: This study aimed to determine whether tumor uptake of F-18-fluorodeoxyglucose (F-18-FDG) is associated with invasive disease-free survival (IDFS) in patients with hormone receptor (HR)-positive ERBB2-negative early-stage breast cancer treated with adjuvant chemotherapy. It was found that the maximum standardized uptake value (SUVmax) on preoperative F-18-FDG positron emission tomography/computed tomography (PET/CT) was independently associated with reduced long-term IDFS. Rating: 9/10
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Letter
Medicine, General & Internal
Muhammet Ozer, Ilyas Sahin, Hassan Abushukair, Aya Abushukair, Anwaar Saeed
Summary: The results of the CheckMate 648 trial demonstrate that nivolumab plus chemotherapy or nivolumab plus ipilimumab can prolong overall survival in patients with advanced esophageal squamous-cell carcinoma compared to chemotherapy alone. This survival benefit is significant among patients with tumor-cell programmed death ligand 1 (PD-L1) expression of 1% or greater.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Yaqing Zhao, Jiazhong Ren
Summary: This study investigated whether metabolism parameters obtained using F-18-FAPI-04 PET/CT can predict PD-L1 expression in patients with LA-ESCC. The results showed that SUVmean, SUVpeak, and SUVsd correlated with PD-L1 expression, with SUVsd being the optimal predictor for PD-L1 positive expression, providing potential guidance for immunotherapy candidate selection.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Dashan Ai, Jinjun Ye, Shihong Wei, Yunhai Li, Hui Luo, Jianzhong Cao, Zhengfei Zhu, Weixin Zhao, Qin Lin, Huanjun Yang, Xiangpeng Zheng, Jialiang Zhou, Guang Huang, Ling Li, Jiancheng Li, Zhi Zhang, Guoren Zhou, Dayong Gu, Mingyu Du, Miao Mo, HuiXun Jia, Zhen Zhang, Kuaile Zhao
Summary: This randomized clinical trial compared the efficacy and adverse events of fluorouracil, cisplatin, and carboplatin in definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma (ESCC). The results showed that paclitaxel plus fluorouracil did not have superior overall survival compared to paclitaxel plus cisplatin or paclitaxel plus carboplatin regimens in locally advanced ESCC. The cisplatin group had higher rates of hematologic and gastrointestinal toxic effects.
Article
Oncology
Keting Li, Wentao Hao, Xianben Liu, Yin Li, Haibo Sun, Shilei Liu, Wenqun Xing, Yan Zheng
Summary: This study compared the efficacy of adjuvant chemotherapy and postoperative observation in patients with esophageal squamous cell carcinoma (ESCC) after neoadjuvant chemotherapy. The results showed that adjuvant chemotherapy did not improve overall survival (OS) in these patients, but it may benefit certain groups of patients.
Article
Immunology
Jiahan Cheng, Minzhang Guo, Yushang Yang, Yilin Liu, Weipeng Hu, Qixin Shang, Chuan Li, Liang Xia, Yun Wang, Wenping Wang, Dong Tian, Yong Yuan, Yang Hu, Longqi Chen
Summary: Neoadjuvant combination of chemotherapy and immunotherapy (NCI) may lead to better treatment outcomes and reduced complications for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Guozhen Yang, Xiaodong Su, Yuanheng Huang, Guangyu Luo, Zhiqiang Wang, Peiqiang Cai, Yating Zheng, Ting Bei, Mengli Huang, Yuezong Bai, Haoqiang He, Jin Xiang, Muyan Cai, Jiudi Zhong, Qiyu Guo, Xu Zhang
Summary: Three cycles of neoadjuvant camrelizumab plus nab-paclitaxel and capecitabine increased tumor regression and improved survival outcomes in patients with locally advanced esophageal squamous cell carcinoma. Randomized controlled trials with larger sample sizes and longer follow-up periods are needed to validate these findings.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Wenwu He, Xuefeng Leng, Tianqin Mao, Xi Luo, Lingxiao Zhou, Jiaxin Yan, Lin Peng, Qiang Fang, Guangyuan Liu, Xing Wei, Kangning Wang, Chenghao Wang, Sha Zhang, Xudong Zhang, Xudong Shen, Depei Huang, Huan Yi, Ting Bei, Xueke She, Wenguang Xiao, Yongtao Han
Summary: This study focuses on locally advanced resectable esophageal squamous cell carcinoma (ESCC), investigating the safety, feasibility, and efficacy of neoadjuvant toripalimab plus paclitaxel and carboplatin treatment. The results indicate that this combination therapy shows potential as a neoadjuvant treatment for ESCC, with increased CD8(+) T cells and decreased M2-type tumor-associated macrophages in responders. Furthermore, certain molecular signatures were associated with treatment response.
Editorial Material
Medicine, General & Internal
David H. Ilson
Summary: Esophageal cancer is a major cause of cancer-related illness and death worldwide, often presenting with locally advanced or metastatic disease due to lack of effective screening or early detection. Esophageal squamous-cell carcinoma is the most common histologic type globally, especially in high-incidence areas like East Asia, while adenocarcinoma dominates in the West. Surgical outcomes for esophageal squamous-cell cancer patients in 1980 highlighted the significant challenge in treating esophageal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Yuting Huang, Jing Chang, Xiaolei Guo, Chao Zhang, Wenping Ji, Shusheng Zhou, Chao Wang, Xu Zhang
Summary: The purpose of this study was to explore the efficacy of induction chemotherapy (IC) in patients with esophageal squamous cell carcinoma (ESCC). The results showed that IC improves the efficacy and survival rate of patients with locally advanced ESCC, especially in subgroups of effective IC, lower pathological grade, smaller tumor diameter, and weekly single-drug concurrent chemotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Wen-yu Yin, Jiao Yuan, Zhi-min Zhang, Cheng Mei, Wei Xu, Yong-xiang Tang, Fang Peng, Ning Li
Summary: Stressed red blood cells showed differences in various indicators compared to untreated red blood cells, being more prone to phagocytosis by macrophages and mainly trapped in the spleen as shown by F-18-FDG PET/CT imaging, while the untreated red blood cells continued to circulate in the system.
SCIENTIFIC REPORTS
(2021)